BeStock  
Stocks › Biotechnology › ELVN

Enliven Therapeutics ELVN

US equityMarket cap rank #2338Biotechnology
$46.53 +$0.12 (+0.26%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $46.53 0.00%
Open$46.05
Prev close$46.41
Day range$45.64 – $47.83
Volume933.6K
Market cap$3.42B
P/E (TTM)–
Dividend yield–

ELVN Stock News

Headlines matching Enliven Therapeutics or the ELVN ticker, most recent first.

  • LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70 PositiveMarket news · 8 Aug 2026 · Direct mention
  • LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $70Market news · 8 Aug 2026 · Direct mention
  • A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $68 to $82Market news · 7 Aug 2026 · Direct mention
  • Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $73 PositiveMarket news · 18 Aug 2026 · Direct mention
  • William Blair Initiates Enliven Therapeutics(ELVN.US) With Buy RatingMarket news · 18 Aug 2026 · Direct mention
  • Barclays Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $78Market news · 18 Aug 2026 · Direct mention
  • Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $82Market news · 14 Aug 2026 · Direct mention
  • H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $64 PositiveMarket news · 9 Jul 2026 · Direct mention
  • Goldman Sachs Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $67 PositiveMarket news · 22 Jul 2026 · Direct mention
  • Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $80 PositiveMarket news · 1 Jul 2026 · Direct mention
  • Stifel Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $60Market news · 9 Jun 2026 · Direct mention
  • Goldman Sachs Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $59Market news · 6 Jun 2026 · Direct mention
  • JonesTrading Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70 PositiveMarket news · 29 Jun 2026 · Direct mention
  • Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $62 PositiveMarket news · 2 Jun 2026 · Direct mention
  • Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $60Market news · 15 Jun 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on ELVN.

Sign in to join the discussion.

Scroll to Top